Drug Markets in Cognitive Dysfunction Will Experience Dramatic Transformation as Total Sales Increase From $300 Million in 2006

WALTHAM, Mass., Jan. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for cognitive dysfunction-which encompasses several distinct disorders-will experience a dramatic overall sales increase, transforming the market from a meager $300 million in 2006 to $3.7 billion in 2016, driven by sales of new drugs from Myriad Genetics, Elan/Wyeth, Targacept/AstraZeneca and Memory Pharmaceuticals/Roche. Four key cognitive dysfunctions are considered in the report-mild cognitive impairment, cognitive impairment associated with schizophrenia, cognitive dysfunction in multiple sclerosis and cognitive dysfunction in traumatic brain injury.

The new Pharmacor report entitled Cognitive Dysfunction finds that the launch of new, expensive therapies over the next several years will boost diagnosis and drug-treatment rates and propel a 12-fold increase in total sales, predominantly in the markets for mild cognitive impairment and cognitive impairment associated with schizophrenia. Myriad Genetics' Flurizan and Elan/Wyeth's bapineuzumab-the first disease-modifying therapies for Alzheimer's disease-will be prescribed off-label in mild cognitive impairment, driving an impressive 56% annual sales growth between 2011 and 2016. Additionally, Targacept/AstraZeneca's ispronicline and Memory Pharmaceuticals/Roche's MEM-3454-the first drugs approved for cognitive impairment associated with schizophrenia-will together fuel a robust 43% growth in sales over this same period.

"Currently, there are no drugs that are unequivocally effective in cognitive dysfunction, and off-label treatment is sporadic as less than one- third of diagnosed patients in any disorder were drug-treated in 2006. However, the impending off-label use of Flurizan and bapineuzumab in mild cognitive impairment coupled with the approvals of several new therapies for cognitive impairment associated with schizophrenia will drive significant market growth," said Jonathan Searles, analyst at Decision Resources. "Additionally, despite the absence of approved therapies, considerable opportunity will remain for agents that effectively treat cognitive dysfunction in multiple sclerosis and traumatic brain injury-these markets benefit from high pricing potential, high prevalence in the case of traumatic brain injury, and low competition."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources